Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ABEO vs CELU: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ABEO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 9–1 Matrix Metrics)
ABEO Overall Winner
6-Pillar Tally: ABEO 4 – 1 CELU (1 Tie)
Matrix Metrics: ABEO 9 – 1 CELU
As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABEO carries a Unified Composite Score of 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin), whereas CELU carries 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin).
- Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ABEO vs CELU
ABEO
Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
$2.42
-1.22% 1D
Market Cap
$167.4M
TTM Revenue
$39M
Forward P/E
18.7x
Beta / 30D Vol
0.60β · 149% Vol
Unified Composite Score
49.9
HOLD
Tech 60.0
Fund 61.0
Flow 67.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
CELU
Celularity Inc. Class A Common Stock
$0.46
-1.05% 1D
Market Cap
$15.2M
TTM Revenue
$19M
Forward P/E
N/M
Beta / 30D Vol
2.01β · 135% Vol
Unified Composite Score
42.9
HOLD
Tech 25.0
Fund 48.0
Flow 67.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ABEO 4 – 1 CELU)
1. Valuation Multiples
ABEO
Forward P/E
18.7x
N/M
Trailing P/E
18.7x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.0x
2.7x
2. Growth & Scale
ABEO
Revenue Growth (YoY)
+2745.0%
-5.3%
Earnings Growth (YoY)
+0.0%
-61.3%
TTM Revenue (USD)
$39M
$19M
Market Cap
$167.4M
$15.2M
3. Profitability & Quality
ABEO
Gross Margin
-3.5%
19.2%
Operating Margin
-186.1%
-254.0%
Net Profit Margin
-160.3%
-245.7%
Return on Equity (ROE)
-42.1%
-6367.2%
4. Balance Sheet & Cash Flow
CELU
Cash Generation (TTM)
-$66M
-$8.9M
Cash Flow Margin
N/A
-47.8%
Net Cash / Leverage
$50M Net Cash
$35M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ABEO
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
165.8% (27th %ile)
116.6% (50th %ile)
Put/Call OI Skew
0.26x (Call-Skewed)
3.60x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ABEO (9) vs CELU (1)| Institutional Metric | ABEO | CELU | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $167.4M | $15.2M | ABEO | |
| Trailing P/E Ratio | 18.7x | N/M | ABEO | |
| Forward P/E Ratio | 18.7x | N/M | ABEO | |
| Revenue Growth (YoY) | +2745.0% | -5.3% | ABEO | |
| Operating Margin (TTM) | -186.1% | -254.0% | ABEO | |
| Net Profit Margin | -160.3% | -245.7% | ABEO | |
| Return on Equity (ROE) | -42.1% | -6367.2% | ABEO | |
| 52-Week Range Position | 6% ($2–$8) | 2% ($0–$3) | ABEO | |
| Beta / 30D Volatility | 0.60β · 149% Vol | 2.01β · 135% Vol | CELU | |
| Unified Institutional Score | 49.9 / 100 (HOLD) | 42.9 / 100 (HOLD) | ABEO | |
| Trailing 12M Revenue (USD) | $39M | $19M | Scale | |
| Gross Profit Margin (TTM) | -3.5% | 19.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.0x EV/Rev | N/M PEG · 2.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$66M ($50M Net Cash) | -$8.9M ($35M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ABEO +10.04 pp
3M Horizon
CELU +19.83 pp
6M Horizon
CELU +8.72 pp
1Y Horizon
ABEO +30.22 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ABEO Revenue | CELU Revenue | ABEO Op. Margin | CELU Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2017 | $0M | N/A | -3325.7% | N/A | ABEO |
| FY2018 | $0M | N/A | -1940.2% | N/A | ABEO |
| FY2020 | $10M | $10M | -814.2% | -1064.0% | ABEO |
| FY2021 | $0M | $20M | -2994.5% | -511.2% | CELU |
| FY2022 | $0M | $20M | -3600.8% | -142.4% | CELU |
| FY2023 | $0M | $20M | -1346.7% | -844.4% | CELU |
| FY2024 | N/A | $50M | N/A | -70.7% | CELU |
| FY2025 | $10M | $30M | -1536.9% | -230.9% | CELU |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ABEO
BREAKDOWN
Current IV
165.8%
IV Percentile
27th %ile
Put/Call OI Skew
0.26x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CELU
BREAKDOWN
Current IV
116.6%
IV Percentile
50th %ile
Put/Call OI Skew
3.60x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ABEO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CELU Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ABEO vs CELU Key Questions & Quantitative Answers
As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABEO carries a Unified Composite Score of 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin), whereas CELU carries 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin). Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABEO leads the Growth & Scale pillar: ABEO posts +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin), compared with CELU at -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), ABEO cumulative revenue shifted +0.0% while CELU shifted +200.0%. In operating R&D and SG&A reinvestment, ABEO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELU.
ABEO screens cheaper on headline valuation multiples. ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 3.0x EV/Revenue (unreported FCF margin), whereas CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABEO (-42.1% ROE) versus CELU (-6367.2% ROE) capital efficiency.
In options market volatility and institutional positioning, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk). By comparison, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CELU vs ABEO · Reverse Pair
ABEO vs ABUS
· Sector Peer
ABEO vs VSTM
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal